Queiro Rubén, Alonso Sara, Burger Stefanie, Pardo Estefanía, Braña Ignacio, Loredo Marta, Alperi Mercedes
Rheumatology Division, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain.
Department of Medicine, Oviedo University School of Medicine, 33011 Oviedo, Spain.
J Pers Med. 2025 Jul 25;15(8):329. doi: 10.3390/jpm15080329.
: Personalized medicine in axial spondyloarthritis (axSpA) requires accurate tools to assess inflammation and tailor disease monitoring. The role of traditional biomarkers such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) remains controversial due to limited sensitivity and variability across disease profiles. : To compare the performance of ESR and CRP in different clinical scenarios of axSpA, including disease activity, functional impact, severity, disease duration, and exposure to biologic therapy. We conducted a cross-sectional analysis of 330 patients with axSpA. Correlations among ESR, CRP, and composite disease indices were evaluated. The discriminatory capacity of each biomarker for relevant clinical thresholds was analyzed using ROC curves and optimal cut-offs identified by the Youden index. : ESR showed broader correlations with disease impact and activity scores than CRP. While both markers had low sensitivity overall, they were highly specific for identifying patients with very high disease activity in select scenarios. ESR ≥ 8.5 mm/h and CRP ≥ 1.88 mg/dL were strongly discriminatory in patients not exposed to biologics. CRP ≥ 0.56 mg/dL showed good performance in early disease. : Both ESR and CRP provide complementary insights into disease activity in axSpA. ESR may offer a broader reflection of disease burden beyond inflammation. These results support a more personalized biomarker strategy in real-world axSpA management, adapted to patient profile and treatment context.
轴性脊柱关节炎(axSpA)的个性化医疗需要准确的工具来评估炎症并调整疾病监测。红细胞沉降率(ESR)和C反应蛋白(CRP)等传统生物标志物的作用仍存在争议,因为其敏感性有限且在不同疾病特征中存在变异性。
为比较ESR和CRP在axSpA不同临床场景中的表现,包括疾病活动度、功能影响、严重程度、疾病持续时间以及生物治疗暴露情况。我们对330例axSpA患者进行了横断面分析。评估了ESR、CRP与综合疾病指数之间的相关性。使用ROC曲线分析每个生物标志物对相关临床阈值的鉴别能力,并通过约登指数确定最佳临界值。
ESR与疾病影响和活动评分的相关性比CRP更广泛。虽然这两种标志物总体敏感性较低,但在特定场景中,它们对识别疾病活动度非常高的患者具有高度特异性。在未接受生物治疗的患者中,ESR≥8.5mm/h和CRP≥1.88mg/dL具有很强的鉴别能力。CRP≥0.56mg/dL在疾病早期表现良好。
ESR和CRP都为axSpA的疾病活动提供了互补的见解。ESR可能比炎症更广泛地反映疾病负担。这些结果支持在现实世界的axSpA管理中采用更个性化的生物标志物策略,以适应患者情况和治疗背景。